Log in to your Inderes Free account to see all free content on this page.
Xbrane Biopharma
0.255 SEK +7.38%2 investors are following this company
Xbrane Biopharma is a biotechnology company. The company specializes in research and development of drugs for the treatment of critical illnesses. Today, the business is focused on research in microspherical technology and in the development of protein molecules. The products are used in the treatment of prostate cancer and endometriosis, as well as in rare and serious eye diseases. The company's head office is located in Solna.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
XBRANE
Daily low / high price
0.238 / 0.255
SEK
Market cap
389.25M SEK
Turnover
1.93M SEK
Volume
7.8M
Latest videos
Financial calendar
Interim report
28.08.2024
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Ashkan Pouya | 11.9 % | 11.9 % |
Håkan Stödberg | 4.7 % | 4.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate
Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® - and run an active partnering process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Redeye: Xbrane Biopharma Q1 2024 - Approaching an eventful second half of the year
![Xbrane Biopharma, Webcast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/411e9613-0432-4929-b319-2f872846e546.png)
Xbrane Biopharma, Webcast with teleconference, Q1, 2024
Xbrane Biopharma releases Interim Report for January-March 2024
![Xbrane Biopharma, Pressconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/00babe22-3db0-40bb-b063-e03d502f97a0.png)
Xbrane Biopharma, Pressconference, 2024
Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
Announcement from Xbrane Biopharma's annual general meeting
![Xbrane Biopharma, Pressconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/54f5ed3b-c9b5-464b-8581-b4e3226fdf22.png)